# US RE49,035 E1 · Traditional Chinese medicine composition, and preparation and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US RE49,035 E1
- Document ID: USRE49035E1
- Status: Granted
- Kind: E1
- Application number: 16/715,485
- Filed: 2019-12-16
- Granted: 2022-04-19
- Earliest claimed: 2013-07-11
- Assignees: Tasly Pharmaceutical Group Co., Ltd.
- Applicants: Tasly Pharmaceutical Group Co., Ltd.
- Inventors: Xijun Yan; Naifeng Wu; Kaijing Yan; Zhengliang Ye; Shunnan Zhang; Lihong Zhou; Wensheng Zhang; Hai'ou Dong
- Web page: https://patentgrep.com/patent/USRE49035E1

## CPC

- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 9/1664: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/1617)}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/2893: {Tablet coating processes (mechanical aspects A61J3/06)}
- A61K 31/045: Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K 31/11: Aldehydes
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 36/258: Panax (ginseng)
- A61K 36/537: Salvia (sage)
- A61K 36/82: Theaceae (Tea family), e.g. camellia
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2068: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/2013)}
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A traditional Chinese medicine composition for treating cardiovascular disease, and a preparation thereof, particularly a micro drop pill preparation thereof, and a method for preparing the preparation; the method for preparing the micro drop pill preparation can be used to prepare drop pills, coated drop pills, and drop pill capsules with a high drug loading capacity.

## Claims

### Claim 1

A Chinese medicine composition consisting of the following materials by weight percentage: 50.0%˜99.9% of Salvia Miltiorrhiza and Panax Notoginseng extract and 0.1%˜50.0% of borneol, wherein the Salvia Miltiorrhiza and Panax Notoginseng extract comprises the following ingredients by weight percentage:
Danshensu:Salvianolic acid T:protocatechuic aldehyde: Salvianolic acid D:rosmarinic acid:Salvianolic acid B:Salvianolic acid A:Panax Notoginseng Saponin R1:Ginsenoside Rg1:Ginsenoside Re:Ginsenoside Rb1:Ginsenoside Rd:dihydrotanshinone I:tanshinone I:cryptotanshinone:tanshinone IIA=(2˜6):(0.5˜2): (1˜3):(0.2˜1):(0.2˜1):(0.5˜2):(0.5˜2):(0.2˜1):(1˜4): (0.1˜0.5):(1˜4):(0.1˜1):(0.01˜0.05):(0.05˜0.1): (0.02˜0.1):(0.1˜0.5).

### Claim 2 (depends on 1)

The Chinese medicine composition according to claim 1, wherein said Chinese medicine composition consists of the following materials by weight percentage: 75.0%˜99.9% of Salvia Miltiorrhiza and Panax Notoginseng extract and 0.1%˜25.0% of borneol.

### Claim 3 (depends on 1)

The Chinese medicine composition according to claim 1, wherein said traditional Chinese medicine composition is composed of the following materials by weight percentage: 90.0%˜99.9% of Salvia Miltiorrhiza and Panax Notoginseng extract and 0.1%˜10.0% of borneol.

### Claim 4 (depends on 1)

The Chinese medicine composition according to claim 1, wherein the Salvia Miltiorrhiza and Panax Notoginseng extract comprises the following ingredients by weight parts:
Danshensu:Salvianolic acid T:protocatechuic aldehyde: Salvianolic acid D:rosmarinic acid:Salvianolic acid B:Salvianolic acid A:Panax Notoginseng Saponin R1: Ginsenoside Rg1:Ginsenoside Re:Ginsenoside Rb1:Ginsenoside Rd:dihydrotanshinone I:tanshinone I:cryptotanshinone:tanshinone IIA=(3˜4):(0.9˜1.2): (1.4˜2.0):(0.5˜0.7):(0.5˜0.9):(1˜1.6):(0.7˜1.2): (0.5˜0.9):(1.8˜2.8):(0.2˜0.4):(1.7˜2.2):(0.2˜0.6): (0.03˜0.04):(0.07˜0.08):(0.05˜0.06):(0.26˜0.28).

### Claim 5 (depends on 4)

The Chinese medicine composition according to claim 4, wherein the Salvia Miltiorrhiza and Panax Notoginseng extract comprises the following ingredients by weight parts:
Danshensu:Salvianolic acid T:protocatechuic aldehyde: Salvianolic acid D:rosmarinic acid:Salvianolic acid B:Salvianolic acid A:Panax Notoginseng Saponin R1: Ginsenoside Rg1:Ginsenoside Re:Ginsenoside Rb1:Ginsenoside Rd:dihydrotanshinone I:tanshinone I: cryptotanshinone: tanshinone IIA=3.6:1.1:1.7:0.6:0.7:1.3:0.9:0.7:2.4:0.3:1.8:0.4:0.03:0.07:0.06:0.27.

### Claim 6 (depends on 1)

The Chinese medicine composition according to claim 1, wherein the Salvia Miltiorrhiza and Panax Notoginseng extract is prepared with the following crude medicine by weight parts: Salvia Miltiorrhiza 75˜90 parts and Panax Notoginseng 10˜25 parts.

### Claim 7 (depends on 6)

The Chinese medicine composition according to claim 6, wherein the Salvia Miltiorrhiza and Panax Notoginseng extract is prepared with the following crude medicine by weight parts: Salvia Miltiorrhiza 82˜84 parts, Panax Notoginseng 16˜17 parts.

### Claim 8 (depends on 1)

A pharmaceutical preparation comprising the Chinese medicine composition according to claim 1 and pharmaceutically acceptable carriers.

### Claim 9 (depends on 8)

The pharmaceutical preparation according to claim 8, wherein said pharmaceutical preparation is in a dosage form of drop pill or micro drop pill, wherein said micro drop pill is prepared with the Chinese medicine composition and drop pill matrix in a ratio of 1:5˜5:1 by weight.

### Claim 10 (depends on 9)

The pharmaceutical preparation according to claim 9, wherein said pharmaceutical preparation is a compound Salvia micro drop pill.

### Claim 11 (depends on 4)

The Chinese medicine composition according to claim 4, wherein said traditional Chinese medicine composition is composed of the following materials by weight percentage: 90.0%˜9.9% of Salvia Miltiorrhiza and Panax Notoginseng extract and 0.1%˜10.0% of borneol.

### Claim 12 (depends on 4)

The Chinese medicine composition according to claim 4, wherein the Salvia Miltiorrhiza and Panax Notoginseng extract is prepared with the following crude medicine by weight parts: Salvia Miltiorrhiza 75-90 parts and Panax Notoginseng 10-25 parts.

### Claim 13 (depends on 4)

A pharmaceutical preparation comprising the Chinese medicine composition according to claim 4 and pharmaceutically acceptable carriers.